23Andme Holding Co (ME)

NASDAQ
2.42
+0.06(+2.54%)
Pre Market
2.45
+0.03(+1.18%)
- Real-time Data
  • Volume:
    1,137,878
  • Day's Range:
    2.35 - 2.46
  • 52 wk Range:
    2.02 - 6.31
Earnings results expected in 14 days

23Andme Holding Co will announce its quarterly financial results in 14 days. Traders should take this into account as the share price often fluctuates around this time period.

ME Overview

Prev. Close
2.36
Day's Range
2.35-2.46
Revenue
297.62M
Open
2.4
52 wk Range
2.02-6.31
EPS
-0.712
Volume
1,137,878
Market Cap
1.1B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,659,861
P/E Ratio
-3.34
Beta
1.75
1-Year Change
-45.12%
Shares Outstanding
455,484,782
Next Earnings Date
Feb 10, 2023
What is your sentiment on 23Andme Holding Co?
or
Market is currently closed. Voting is open during market hours.

23Andme Holding Co News

23Andme Holding Co Analysis

23Andme Holding Co Company Profile

23Andme Holding Co Company Profile

23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company's segments include Consumer & Research Services and Therapeutics. The Consumer & Research Services segment comprises its Personal Genome Service (PGS), telehealth business, and research services. Its PGS service provides customers with a suite of genetic reports, including information on customers genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. Its telehealth platform provides patients with access to medical consultation and treatment. Through its research services, it uses its database of genetic and phenotypic information to identify targets for drug development. The Therapeutics segment focuses on the use of genetic insights from its database of genetic and phenotypic information to develop therapies to improve patients lives.

Read More

Analyst Price Target

Average5.69 (+135.02% Upside)
High7.00
Low3.75
Price2.42
No. of Analysts4
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuySellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Sell
  • kidding me?
    0
    • ⭕️
      0
      • nobody interested in 23
        0
        • 🚀🚀🚀
          1
          • 23andMe Agrees to Acquire Lemonaid Health. The purchase price is 400m, of which 25% cash and 75% in shares calculated on a fixed value of 8.82 per share. So 34m new shares to be issued.
            2
            • ME (T) 1 10.19
              0
              • $20 soon?
                1
                • What's the news boys?
                  0
                  • Why the surge?
                    0
                    • EMJ Capital founder and president Eric Jackson named it one of his stock picks on CNBC's "Closing Bell."
                      1
                      • thank you, looking into EMJ and Eric Jackson now.
                        0